Last reviewed · How we verify
Rimegepant for acute migraine treatment (rimegepant-for-acute-migraine-treatment)
Rimegepant for acute migraine treatment (generic name: rimegepant-for-acute-migraine-treatment) is a calcitonin gene-related peptide receptor antagonist drug developed by Pfizer. It is currently FDA-approved for Acute treatment of migraine with or without aura in adults.
Rimegepant targets the calcitonin gene-related peptide receptor to treat acute migraine.
Rimegepant, developed by Pfizer, holds a significant position in the acute migraine treatment market, targeting the calcitonin gene-related peptide receptor. Despite having one approved indication, its competitive advantage is somewhat limited by the presence of comparably effective alternatives like Ubrogepant and Zavegepant, which have similar or slightly better NNT values. A key risk for Rimegepant is the strong competition from established treatments such as Triptans, which offer higher efficacy. The lack of ongoing clinical trials and the requirement for a PD-L1 companion diagnostic for several indications may further impact its pipeline outlook.
At a glance
| Generic name | rimegepant-for-acute-migraine-treatment |
|---|---|
| Sponsor | Pfizer |
| Drug class | calcitonin gene-related peptide receptor antagonist |
| Target | calcitonin gene-related peptide receptor |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Mechanism of action
Rimegepant is a calcitonin gene-related peptide receptor antagonist. This mechanism of action is based on the understanding that calcitonin gene-related peptide plays a crucial role in migraine pathophysiology. By blocking this receptor, rimegepant reduces the frequency and severity of migraines. This approach offers a novel treatment option for patients with acute migraine.
Approved indications
- Acute treatment of migraine with or without aura in adults
Common side effects
- COVID-19
- Upper respiratory tract infection
- Nasopharyngitis
- Hyperuricaemia
- Hyperlipidaemia
- Weight increased
- Pyrexia
- Urinary tract infection
- Hepatic function abnormal
- Anaemia
- Blood creatine phosphokinase increased
- Weight decreased
Drug interactions
- P-glycoprotein inhibitors (e.g., quinidine, verapamil)
- Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)
- Strong CYP3A4 inducers (e.g., rifampin, carbamazepine)
- CYP3A4 substrates (e.g., midazolam, simvastatin)
- Warfarin
- Benzodiazepines (e.g., alprazolam, clonazepam)
- Opioids (e.g., fentanyl, oxycodone)
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rimegepant for acute migraine treatment CI brief — competitive landscape report
- Rimegepant for acute migraine treatment updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Rimegepant for acute migraine treatment
What is Rimegepant for acute migraine treatment?
How does Rimegepant for acute migraine treatment work?
What is Rimegepant for acute migraine treatment used for?
Who makes Rimegepant for acute migraine treatment?
What is the generic name of Rimegepant for acute migraine treatment?
What drug class is Rimegepant for acute migraine treatment in?
What development phase is Rimegepant for acute migraine treatment in?
What are the side effects of Rimegepant for acute migraine treatment?
What does Rimegepant for acute migraine treatment target?
Related
- Drug class: All calcitonin gene-related peptide receptor antagonist drugs
- Target: All drugs targeting calcitonin gene-related peptide receptor
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Acute treatment of migraine with or without aura in adults
- Compare: Rimegepant for acute migraine treatment vs similar drugs
- Pricing: Rimegepant for acute migraine treatment cost, discount & access